Eculizumab for the acute attack of neuromyelitis optica spectrum disorder
Eculizumab may yield favorable outcomes in acute NMOSD attacks, with infection monitoring being particularly important in severe cases.
Authors
- Wenjuan Huang (ORCID: https://orcid.org/0000-0002-8056-373X)
- Jian Yu (ORCID: https://orcid.org/0000-0002-5042-9345)
- Yuxin Fan (ORCID: https://orcid.org/0009-0006-7784-7340)
- Cynthia Quan (ORCID: https://orcid.org/0009-0005-4269-3903)
- Yiqin Xiao (ORCID: https://orcid.org/0000-0002-6058-113X)
- Jingzi ZhangBao (ORCID: https://orcid.org/0000-0002-5308-6325)
- Lei Zhou (ORCID: https://orcid.org/0000-0002-7145-4953)
- Zhouzhou Wang
- Xiang Li (ORCID: https://orcid.org/0000-0002-9918-5847)
- Min Wang (ORCID: https://orcid.org/0000-0002-3420-4031)
- Liang Wang (ORCID: https://orcid.org/0000-0001-6140-914X)
- Hongmei Tan (ORCID: https://orcid.org/0000-0002-3141-7920)
- Qingqing Zhuang
Institutions
- Wenzhou Medical University (CN)
- Wenzhou Central Hospital (CN)
- National Institute of Neurological Disorders and Stroke (US)
- Eye & ENT Hospital of Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1645401
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- National Natural Science Foundation of China